Sugi Predict

Sugi Predict / Compounds / SCHEMBL796213

SCHEMBL796213

SCHEMBL796213

Oc1ccnc2ccc(Cl)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.39
▸ NQO2 P16083 1/20 0.38
▸ MAPT P10636 4/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ METAP2 P50579 2/20 0.35
▸ METAP1 P53582 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ MMP2 P08253 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ COMT P21964 1/20 0.35
▸ ADRA1A P35348 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ KDM4E B2RXH2 5/20 0.35
▸ HSP90AA1 P07900 3/20 0.35
▸ LMNA P02545 3/20 0.35
▸ BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29472071 1.00 ACHE (0.39) ACHENQO2MAPTKMT2AMETAP2
SCHEMBL23147517 0.79 CRHBP (0.36) MAPTKMT2AALDH1A1KDM4ELMNA
SCHEMBL29472081 0.76 ACHE (0.39) ACHENQO2MAPTKMT2AMETAP2
SCHEMBL21199865 0.76 ACHE (0.39) ACHENQO2MAPTKMT2AMETAP2
SCHEMBL29582518 0.76 ACHE (0.39) ACHENQO2MAPTKMT2AMETAP2
SCHEMBL24422536 0.76 ACHE (0.39) ACHENQO2MAPTKMT2AMETAP2
SCHEMBL31745274 0.76 EGFR (0.40) NQO2ADRA1AEGFRRPS6KA5RPS6KA4
SCHEMBL22715644 0.76 NR4A2 (0.47) MAPTKMT2ATSHRALDH1A1GAA
SCHEMBL30625762 0.76 METAP2 (0.50) ACHEMAPTKMT2AMETAP2METAP1
SCHEMBL3375315 0.76 METAP2 (0.50) ACHEMAPTKMT2AMETAP2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 — — US disclosed
US-12371428-B2 Pyridone compounds and methods of use EXELIXIS, INC. (US) 2025-07-29 — — US disclosed
EP-4467199-A2 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2024-11-27 — — EP disclosed
EP-3976597-B1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2024-08-28 — — EP disclosed
US-20240199605-A1 SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2024-06-20 — — US disclosed
US-11827634-B2 Small molecule inhibitors of NF-kB inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 — — US disclosed
WO-2023165581-A1 PYRIDINE DERIVATIVE AND USE THEREOF 四川汇宇制药股份有限公司 2023-09-07 — — WO disclosed
US-20230080834-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2023-03-16 — — US disclosed
US-20220315579-A1 PYRIDONE COMPOUNDS AND METHODS OF USE EXELIXIS, INC. 2022-10-06 — — US disclosed
WO-2022182845-A1 MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2022-09-01 — — WO disclosed
US-20150057293-A1 NEW COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2015-02-26 — — US disclosed
WO-2014079364-A1 IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 北京富龙康泰生物技术有限公司 (CN) 2014-05-30 — — WO disclosed
US-20130190307-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2013-07-25 — — US disclosed
US-20130190307-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2013-07-25 — — US disclosed
US-20130190307-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2013-07-25 — — US disclosed
EP-2616468-A1 FUSED HETEROARYLS AND THEIR USES Hutchison Medipharma Limited (CN) 2013-07-24 — — EP disclosed
WO-2013061077-A1 NEW COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2013-05-02 — — WO disclosed
CN-102399218-A Triheterocyclic compounds and their use as PI3K inhibitors HUTCHISON MEDIPHARMA LTD 2012-04-04 — — CN disclosed
WO-2012034526-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2012-03-22 — — WO disclosed
WO-2012034526-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2012-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057293-A1 NEW COMPOUNDS NQO1, NTPCR, NDC1 ACHE 1803/4885NQO2 11/4885MAPT 1673/4885
US-12371428-B2 Pyridone compounds and methods of use PDXK, PLK2, MAP4K2 ACHE 2048/4885NQO2 888/4885MAPT 2493/4885
US-20230080834-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, NFRKB ACHE 4753/4885NQO2 1719/4885MAPT 1462/4885
US-11827634-B2 Small molecule inhibitors of NF-kB inducing kinase NFKBIA, IKBKB, NFRKB ACHE 4753/4885NQO2 1719/4885MAPT 1462/4885
US-20130190307-A1 FUSED HETEROARYLS AND THEIR USES FARS2, TIAL1, DHFR ACHE 259/4885NQO2 2570/4885MAPT 2577/4885
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase IRAK3, IKBKB, IKBKG ACHE 4878/4885NQO2 1881/4885MAPT 4109/4885
US-20240199605-A1 SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, IKBKE ACHE 4807/4885NQO2 1666/4885MAPT 1841/4885
US-20220315579-A1 PYRIDONE COMPOUNDS AND METHODS OF USE PDXK, PLK2, MAP4K2 ACHE 2048/4885NQO2 888/4885MAPT 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.